We found that the aFGF-NP + CPMBs combined with UTMD could increase EF and FS, as well as decrease LVIDs, LVIDd, and BNP, compared with the DOX-HF group, which proved to prevent the deterioration of cardiac function induced by doxorubicin. The gene discussed is FGF1; the disease is hydrops fetalis.